Basic Ranexa Information

• INN (International Nonproprietary Name): Ranolazine.
• Brand Names Available In Canada (English): Corzyna; Ranexa.
• ATC Code: C01EB18 (Antianginal Drugs, Other Antianginal Agents).
• Forms & Dosages: Extended‑release oral tablets available as 375 mg, 500 mg, 750 mg and 1000 mg strengths; 1000 mg strength is primarily available in Canada and Australia.
• Manufacturers In Canada (English): Bausch Health and other distributors; generics may be available in some markets.
• Registration Status In Canada (English): Prescription‑only and approved for chronic stable angina under specialist supervision.
• OTC / Rx Classification: Prescription‑only (Rx).

Latest Research Highlights

Worried whether ranolazine really helps chest pain long term?

International randomized controlled trials and pooled analyses from 2022–2025 continue to support ranolazine’s symptomatic benefit for chronic stable angina.

These studies report fewer weekly angina episodes and modest improvement in exercise tolerance without major effects on heart rate or blood pressure.

Health Canada–approved indications align with these findings and support specialist‑directed use as add‑on therapy.

Canadian randomized trial data are limited, with most national contributions coming from observational registries and pharmacovigilance reports focused on tolerability.

Emerging 2022–2025 research is exploring ranolazine’s role in atrial fibrillation prevention and refractory microvascular angina, but those results remain preliminary and investigational.

Post‑marketing safety reviews emphasise QT monitoring in at‑risk populations and interactions via CYP3A metabolism.

Data Highlight: QT prolongation has been reported rarely in pharmacovigilance reports, and discontinuation due to adverse events is uncommon in registry data.

Clinical Effectiveness In Canada

Are Canadian patients seeing the same benefits reported elsewhere?

Health Canada authorizes ranolazine for chronic stable angina as an add‑on when standard agents are insufficient or not tolerated.

The product monograph and the Health Canada Drug Product Database list recommended dosing and monitoring details for prescribers and pharmacists.

Provincial formularies differ widely; some provinces place ranolazine on specialist‑only or limited‑benefit schedules and many require prior authorization for coverage.

Real‑world Canadian data from registries echo international RCT findings: symptom reduction and tolerability similar to trial results.

In practice, cost and formulary constraints frequently determine patient access and uptake in Canada.

Patient Note: Counsel that ranolazine reduces symptoms rather than curing underlying coronary disease, and check provincial coverage steps such as prior authorization or specialist prescription.

Indications And Expanded Uses

Is ranolazine only for classic angina, or is it used for other heart problems?

Approved (Health Canada)

Chronic stable angina in adults as add‑on therapy when standard antianginal agents are insufficient or not tolerated.

Off‑Label / Investigational

Atrial fibrillation prevention (small studies), symptomatic microvascular angina, and preliminary work in diastolic dysfunction — evidence remains investigational.

Clinical Tip: Document informed consent for any off‑label use and follow specialist guidance, as provincial plans typically do not reimburse off‑label prescriptions.

Composition And Brand Landscape In Canada

Which ranolazine products might appear in a Canadian prescription or pharmacy shelf?

The active ingredient is ranolazine in extended‑release oral tablet form.

In Canada, marketed brands include Corzyna and Ranexa, commonly supplied as 500 mg and 1000 mg ER tablets.

Manufacturers and distributors supplying Canadian markets include Bausch Health and other regional suppliers; generics may be available depending on patent and supply.

Packaging in Canada follows bilingual labelling, with French translations such as "comprimés à libération prolongée" on francophone labels.

• Bottle vs blister packs may vary by supplier and pharmacy.
• Pharmacists should confirm product‑specific DINs and package sizes before substitution.

Contraindications And Special Precautions

Who should definitely not take ranolazine, and who needs extra monitoring?

• Absolute Contraindications: known hypersensitivity to ranolazine, severe hepatic impairment, concomitant use with strong CYP3A inhibitors (for example, ketoconazole, clarithromycin), and pre‑existing QT prolongation syndromes.
• Relative Precautions: moderate hepatic impairment (dose adjust or avoid), severe renal impairment (not recommended), age over 75 years (closer monitoring advised), and history of arrhythmia.

When To Avoid Ranolazine: Avoid in severe liver disease, with strong CYP3A inhibitors, and in patients with baseline QT prolongation.

Hepatic Guidance

Contraindicated in severe hepatic impairment; use caution and dose reduction may be required in moderate impairment.

Renal Guidance

Not recommended in severe renal impairment; use caution in mild to moderate impairment.

Consider vulnerable Canadian groups such as older adults with polypharmacy, rural patients with limited ECG access, and Indigenous patients who may face access barriers; apply culturally safe care and thorough medication reconciliation.

Dosage Guidelines

How should ranolazine be started and adjusted for most adults in Canada?

Standard adult initiation is ranolazine extended‑release 500 mg orally twice daily.

Titrate to 1000 mg twice daily based on symptom response and tolerability, without exceeding 2000 mg per day.

Tablets are extended‑release and must be swallowed whole; do not crush or chew.

• Patient Counselling: take at the same times each day, do not double doses if missed, and do not crush or split ER tablets.
• Pediatric dosing is not established and should not be attempted outside clinical trials.

Interactions Overview

Could a common antibiotic, supplement or grapefruit juice make ranolazine risky?

Ranolazine is primarily metabolized by CYP3A and to a lesser extent by CYP2D6, so strong CYP3A inhibitors increase ranolazine exposure and QT risk.

Strong CYP3A inhibitors include some azole antifungals and macrolide antibiotics such as clarithromycin; these combinations should be avoided.

Also avoid co‑administration with other QT‑prolonging medicines and advise patients to avoid grapefruit and grapefruit juice, which inhibit CYP3A.

Pharmacists should run a full medication review including over‑the‑counter and natural products, and flag high‑risk combinations to prescribers.

Cultural Perceptions And Patient Habits

What do Canadian patients actually ask about when ranolazine comes up?

Online patient forums and support groups commonly raise questions about cost, bilingual packaging, and whether an added antianginal is worth the benefit.

Patients report valuing clear explanations from cardiologists and pharmacists and want upfront information on likely side effects such as constipation and dizziness.

Rural and remote patients frequently describe longer waits for specialist ECG monitoring and fewer local pharmacy options, while urban patients often find brand options stocked in major chains.

Indigenous and Francophone communities prefer culturally appropriate counselling and bilingual materials to improve adherence and safety.

Provide links to provincial patient support services and manufacturer assistance programs to help with affordability and access where available.

Availability And Pricing Patterns

How easy is it to get ranolazine in Canada and what will it cost?

Ranolazine ER (Corzyna, Ranexa) is available in Canada through major pharmacy chains and hospital pharmacies, typically in 500 mg and 1000 mg strengths.

Coverage varies by province and plan, with some public formularies requiring prior authorization or specialist prescribing for reimbursement.

Retail prices and co‑payments differ by pharmacy and by whether provincial coverage applies.

Cross‑border pricing comparisons sometimes show lower US prices for specific strengths, but routine cross‑border purchasing is limited by export/import rules and prescription validity.

Online Canadian pharmacies can legally supply prescription medications where permitted, but purchasers should verify licencing and avoid counterfeit risk.

Tip: in this online pharmacy ranexa can be ordered with discreet delivery across Canada in 5–14 days when a valid prescription is supplied.

Comparable Medicines And Preferences

When should ranolazine be chosen over a beta‑blocker, calcium‑channel blocker or nitrate?

Common alternatives on Canadian formularies include nitrates (isosorbide dinitrate/mononitrate), calcium‑channel blockers (amlodipine, diltiazem, verapamil), and β‑blockers (metoprolol, bisoprolol).

Ranolazine’s clinical niche is symptom improvement without significant reductions in heart rate or blood pressure, making it useful for patients who cannot tolerate haemodynamic effects.

For refractory angina, coordinate with cardiology and consider non‑pharmacologic options such as cardiac rehabilitation or revascularization when appropriate.

FAQ

1. Is ranolazine covered by my provincial drug plan?

   Coverage varies by province; check provincial formularies such as Ontario Drug Benefit, BC PharmaCare and RAMQ, and ask a pharmacist about prior authorization requirements.

2. What side effects should I watch for?

   Common side effects include constipation, nausea, headache and dizziness; seek immediate care for fainting, palpitations or any signs of severe arrhythmia due to potential QT prolongation.

3. Can I take ranolazine with my other heart medicines?

   Many combinations are used safely, but avoid strong CYP3A inhibitors and other QT‑prolonging drugs; always bring a complete medication list to the pharmacist for review.

4. What if I live in a rural community?

   Talk to your care team about longer refill supplies, telehealth cardiology consults, and arranging local ECG monitoring; pharmacists can often coordinate renewals with specialists.

Emergency Checklist: If a patient experiences syncope, severe dizziness, chest pain or palpitations, advise immediate emergency care and bring medication details.

Guidelines For Proper Use

What should pharmacists and prescribers check before dispensing ranolazine?

• Confirm the indication and whether a specialist is involved in the patient’s cardiovascular care.
• Review the full medication list for CYP3A inhibitors and QT‑prolonging agents and advise on avoidance of grapefruit juice.
• Counsel on dosing schedule (ER tablets twice daily), safe handling (do not crush) and missed dose instructions.
• Recommend baseline ECG and periodic monitoring in high‑risk patients, particularly the elderly and those with electrolyte disturbances.
• Document informed consent for off‑label uses and retain records of prior authorization or subsidy applications.

What The Prescriber Must Provide

Diagnosis, specialist letter when required for reimbursement, relevant lab results (liver/renal), and current medication list.

What The Pharmacist Must Verify

Appropriate dosing, interactions, provincial coverage requirements, and patient counselling completed.

Storage: keep at 20–25°C and advise patients to keep tablets in original packaging and out of reach of children.

Delivery Across Canada (English)